Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor

KRAS , the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS , selective inhibition of KRAS presents a significant challenge due to the requirement of inhibitors to bind KRAS with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS mutant xenograft mouse tumor model.